|
|
Prepublished online as a Blood First Edition Paper on April 17, 2003; DOI 10.1182/blood-2003-01-0227.
 Previous Article | Table of Contents | Next Article 
Blood, 1 August 2003, Vol. 102, No. 3, pp. 934-939
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Plasminogen activator inhibitor type–1 deficiency does not influence the outcome of murine pneumococcal pneumonia
Anita W. Rijneveld,
Sandrine Florquin,
Paul Bresser,
Marcel Levi,
Vivian de Waard,
Roger Lijnen,
Jaring S. Van der Zee,
Peter Speelman,
Peter Carmeliet, and
Tom van der Poll
From the Academic Medical Center, University of Amsterdam, The Netherlands; the Department of Experimental Internal Medicine, Department of Internal Medicine, Department of Pathology, Department of Pulmonology, Department of Biochemistry, Department of Infectious Diseases, Tropical Medicine and AIDS, and Center for Molecular and Vascular Biology, University of Leuven, Louvain; and the Center for Transgene Technology and Gene Therapy, Louvain, Belgium
Urokinase-type plasminogen activator (uPA) and its receptor uPAR are components of the fibrinolytic system and are important for an adequate immune response to respiratory tract infection, in part through their role in the migration of inflammatory cells. PA inhibitor–1 (PAI-1) is the predominant inhibitor of soluble and receptor-bound uPA. To determine the role of PAI-1 in host defense against pneumococcal pneumonia, the following studies were performed: (1) Patients with unilateral community-acquired pneumonia demonstrated elevated PAI-1 concentrations together with decreased PA activity in bronchoalveolar lavage fluid (BALF) obtained from the infected, but not from the contralateral, site. (2) Mice with Streptococcus pneumoniae pneumonia displayed elevated PAI-1 protein and mRNA levels in their lungs. (3) PAI-1 gene–deficient mice, however, had an unaltered immune response to pneumococcal pneumonia, as measured by cell recruitment into lungs, bacterial outgrowth, and survival. Furthermore, plasminogen-gene–deficient mice also had an unremarkable defense against pneumococcal pneumonia. These data indicate that pneumonia is associated with inhibition of the fibrinolytic system at the site of the infection secondary to increased production of PAI-1; an intact fibrinolytic response is not required for an adequate host response to respiratory tract infection, however, suggesting that the previously described role of uPA and uPAR are restricted to their function in cell migration.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. B. Allen, M. E. Cloutier, Y. C. Larrabee, K. Tetenev, S. T. Smiley, and J. H. T. Bates
Neither fibrin nor plasminogen activator inhibitor-1 deficiency protects lung function in a mouse model of acute lung injury
Am J Physiol Lung Cell Mol Physiol,
March 1, 2009;
296(3):
L277 - L285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Haitsma, M. J. Schultz, J-J. H. Hofstra, J. W. Kuiper, J. Juco, R. Vaschetto, M. Levi, H. Zhang, and A. S. Slutsky
Ventilator-induced coagulopathy in experimental Streptococcus pneumoniae pneumonia
Eur. Respir. J.,
December 1, 2008;
32(6):
1599 - 1606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yende, D. C. Angus, J. Ding, A. B. Newman, J. A. Kellum, R. Li, R. E. Ferrell, J. Zmuda, S. B. Kritchevsky, T. B. Harris, et al.
4G/5G Plasminogen Activator Inhibitor-1 Polymorphisms and Haplotypes Are Associated with Pneumonia
Am. J. Respir. Crit. Care Med.,
December 1, 2007;
176(11):
1129 - 1137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Renckens, J. J. T. H. Roelofs, P. I. Bonta, S. Florquin, C. J. M. de Vries, M. Levi, P. Carmeliet, C. van't Veer, and T. van der Poll
Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia
Blood,
February 15, 2007;
109(4):
1593 - 1601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. T. Keller, K. F. van der Sluijs, M. D. de Kruif, V. E. A. Gerdes, J. C. M. Meijers, S. Florquin, T. van der Poll, E. C. M. van Gorp, D. P. M. Brandjes, H. R. Buller, et al.
Effects on Coagulation and Fibrinolysis Induced by Influenza in Mice With a Reduced Capacity to Generate Activated Protein C and a Deficiency in Plasminogen Activator Inhibitor Type 1
Circ. Res.,
November 24, 2006;
99(11):
1261 - 1269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-Q. Wang, K. Bdeir, S. Yarovoi, D. B. Cines, W. Fang, and E. Abraham
Involvement of the Urokinase Kringle Domain in Lipopolysaccharide-Induced Acute Lung Injury
J. Immunol.,
October 15, 2006;
177(8):
5550 - 5557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Arndt, S. K. Young, and G. S. Worthen
Regulation of Lipopolysaccharide-Induced Lung Inflammation by Plasminogen Activator Inhibitor-1 through a JNK-Mediated Pathway
J. Immunol.,
September 15, 2005;
175(6):
4049 - 4059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Choi, M.J. Schultz, J.W.O. van Till, P. Bresser, J.S. van der Zee, M.A. Boermeester, M. Levi, and T. van der Poll
Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection
Eur. Respir. J.,
November 1, 2004;
24(5):
786 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M J Schultz, J Millo, M Levi, C E Hack, G J Weverling, C S Garrard, and T van der Poll
Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia
Thorax,
February 1, 2004;
59(2):
130 - 135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
